Latest News

Roche gets FDA priority review for atezolizumab

PD-L1 (programmed death-ligand 1), which is expressed on tumour cells and tumour-infiltrating immune cells, interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, atezolizumab can trigger activation of T cells, restoring their ability to effectively detect and attack tumour cells. © Genentech


by tg

Roche is expanding its indications in cancer immunotherapy. Following FDA approvals of its PD-L1 checkpoint inhibitor atezolizumab in NSCLC and bladder cancer patients refractive to platinum-based chemotherapy, the Swiss pharma major is awaiting a FDA decision on whether the antibody is suitable as first-line treatment in a further subpopulation of bladder cancer patients.

Based on results of a single arm Phase II study, the FDA granted atezolizumab Priority Review in an additional type of advanced bladder cancer. While the agency granted accelerated market approval in May 2016 for the anti-PD-L1 antibody in patients who were treatment-refractive to platinum-based chemotherapy in neoadjuvant or adjuvant setting, the current priority review extends treatment options. Until April 2017, the agency will decide on the approval of atezolizumab in patients with bladder cancer not eligible for cisplatin chemotherapy (first-line treatment) or disease progression after 12 months of cisplatin therapy before or after surgery.

Roche’s supplemental biologics license application (sBLA) submission for atezolizumab is based on results from the Phase II IMvigor210 study. IMvigor210 is an open-label, single-arm Phase II study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic bladder cancer, regardless of PD-L1 expression. The primary endpoint of the study was objective response rate (ORR). Secondary endpoints included duration of response (DOR), overall survival (OS), progression-free survival (PFS) and safety.

Evotec acquires stake in Exscientia

Evotec AG (Hamburg, Germany) has acquired a minority stake in Exscienta Ltd., a pioneer in self-learning systems for drug discovery. The...

Why to watch out Spain

More than 100 people joined the first edition of this event organised by the Spanish biotech organisation ASEBIO end of September in the Barcelona...

Microbiome shows COPD subtypes

The findings lay the foundations for a more personalised treatment of the disorder that mostly affects smokers. “COPD has various subtypes that can...

Smartwatch for patient monitoring

The new self-learning algorithm enables smartwatches to detect and record your every move, without being told beforehand what to look for. Current...

GSK cancels 30 preclinical and clinical programmes

She will focus on the “real winners”, GlaxoSmithKline’s new chief executive, Emma Walmsley, said when she presented the Q2 results of the company in...

TC Biopharm gets €4m Horizon2020 grant

TC Biopharm Ltd. (TCB) gets a €4m funding from the European Union’s Horizon 2020 research and innovation programme. TCB will progress its...

Macrophage Pharma backed by Merck Ventures

Merck Ventures extended the £9m (€9.8m) Series A investment made by CRT Pioneer Fund, Novo Holdings A/S and Aglaia Biomedical Ventures BV in January...